GleamWall
中文EN

ADVB Advanced Biomed Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1941029 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY279.7%
TTM EPS YoY244.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE85.0%
ROA63.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets12.5%
Debt / equity0.00x
Current ratio8.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.25x
Accruals ratio79.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue————————
R&D expense——$243,226$186,331$235,992$234,225$219,966$212,397
SG&A expense$973,931$3.98M$276,610$210,311$147,155$611,377$347,541$67,667
Operating income-$973,931———-$147,155———
Pretax income-$989,054-$12.52M-$488,942$7.00M-$147,155$675,636-$1.20M-$579,494
Net income-$989,054$694,999-$488,942$6.86M-$386,901-$701,611-$1.38M-$907,904
EBITDA————-$99,163———
EPS (basic)-0.60—-0.380.31-0.36—-1.35-0.05
EPS (diluted)-0.60—-0.380.31-0.36—-1.35-0.05
Weighted avg. shares (diluted)1.65M—1.28M21.64M1.08M—1.02M20.00M
Balance sheet
Cash & equivalents$213,995$385,535$2.60M$2.60M$12,644$31,139$3.18M$2.65M
Current assets$12.87M$13.75M$10.53M$10.73M$5.84M$22.38M$7.73M$3.14M
PP&E, net——$87,280$97,100$281,270$125,184$355,274$401,007
Intangibles——————$20,325$50,516
Total assets$12.90M$13.75M$10.65M$10.85M$6.24M$22.86M$8.29M$4.50M
Current liabilities$1.59M$1.47M$1.43M$1.25M$3.04M$19.24M$4.11M$3.83M
Total liabilities$1.61M$1.47M$1.44M$1.37M$3.24M$19.38M$4.16M$3.89M
Shareholders' equity$11.29M$12.28M$9.21M$9.48M$3.00M$3.48M$4.13M$619,032
Shares outstanding1.65M1.65M1.38M21.64M21.64M1.08M21.64M20.00M
Cash flow statement
Operating cash flow-$171,464-$583,268-$239,775-$513,558-$610,342-$1.54M-$3.41M-$841,841
Capital expenditure——$1,264$12,906$1,771$20,149$2,215-$10,692
Free cash flow——-$241,039-$526,464-$612,113-$1.56M-$3.41M-$831,149
Investing cash flow—-$2.49M-$1,264-$12,906-$1,771-$20,149-$2,215$10,692
Financing cash flow—$936,756$268,277$315,477$447,462-$765,466$5.90M$408,286
Depreciation & amortization——$9,326$14,462$47,992$275,865$22,507$21,983

Free plan shows the latest 8 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.